Beyond Air CFO buys 4,340 shares and warrants

Rhea-AI Filing Summary

Beyond Air, Inc. Chief Financial Officer Daniel J. Moorhead reported purchases on 2026-07-29 of 4,340 shares of common stock at $5.76 per share, along with 4,340 Series A Warrants and 4,340 Series B Warrants, each exercisable for common stock at $5.51 per share. The Series A Warrants are exercisable immediately and expire on the earlier of one year from issuance or 45 days after FDA approval of the company’s pending premarket approval supplement for LungFit PH II, while the Series B Warrants expire five years after issuance. Following these transactions, Moorhead holds 4,340 common shares, 4,340 Series A Warrants and 4,340 Series B Warrants directly.

Insider Trade Summary

Net Buyer: 13,020 shares

Net Buy 3 txns

Insider MOORHEAD DANIEL J

Role Chief Financial Officer

Bought 13,020 shs

Type	Security	Shares	Price	Value
Purchase	Series A Warrant F3, F1, F2	4,340	--	--
Purchase	Series B Warrant F3, F1, F4	4,340	--	--
Purchase	Common Stock	4,340	$5.76	$25K

Holdings After Transaction: Series A Warrant — 4,340 contracts (Direct); Series B Warrant — 4,340 contracts (Direct); Common Stock — 4,340 shares (Direct)

Footnotes (4)

1. F1. Exercisable immediately upon issuance
2. F2. Expiration on the earlier of (i) the first anniversary of their issuance or (ii) the date that is 45 days following approval by the FDA of the Company's pending premarket approval supplement for LungFit PH II
3. F3. Each Series A Warrant and Series B Warrant was purchased together with one share of common stock for a combined purchase price of $5.76.
4. F4. 5 years following date of issuance

Key Figures

Common shares purchased: 4,340 shares Series A Warrants purchased: 4,340 warrants Series B Warrants purchased: 4,340 warrants +3 more

6 metrics

Common shares purchased 4,340 shares Shares of common stock purchased on 2026-07-29

Series A Warrants purchased 4,340 warrants Series A Warrants acquired on 2026-07-29

Series B Warrants purchased 4,340 warrants Series B Warrants acquired on 2026-07-29

Common stock purchase price $5.76 per share Price paid for common stock on 2026-07-29

Warrant exercise price $5.51 per share Exercise price for both Series A and Series B Warrants

Total securities purchased 13,020 Sum of common shares, Series A Warrants and Series B Warrants acquired

Key Terms

Series A Warrant, Series B Warrant, premarket approval supplement, LungFit PH II

4 terms

Series A Warrant financial

"Each Series A Warrant and Series B Warrant was purchased together with one share"

A Series A warrant is a contract issued alongside a company’s early funding round that gives the holder the right to buy a set number of shares later at a fixed price. Think of it like a coupon that lets an investor purchase stock at today’s agreed price even if the company’s value rises; it can boost potential upside for the warrant holder and create dilution for existing shareholders, so investors watch them when assessing ownership and future share value.

Series B Warrant financial

"Each Series A Warrant and Series B Warrant was purchased together with one share"

A Series B warrant is a tradable right issued alongside a Series B funding round that lets its holder buy a specified number of company shares at a fixed price for a set period. It matters to investors because exercising the warrant increases the total shares outstanding (dilution) and can be a cheap way to gain ownership if the company’s value rises — think of it like a coupon to buy stock later at today’s price.

premarket approval supplement medical

"the Company’s pending premarket approval supplement for LungFit PH II"

A premarket approval supplement is a regulatory submission seeking permission to change a medical device that already has FDA premarket approval, similar to asking a regulator for permission to alter a certified product before selling the new version. For investors, it matters because the supplement triggers a review that can affect how quickly a revised device reaches the market, add development or compliance costs, and change future sales or competitive positioning.

LungFit PH II medical

"approval by the FDA of the Company’s pending premarket approval supplement for LungFit PH II"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Beyond Air (XAIR)'s CFO buy in the latest Form 4 filing?

Beyond Air’s CFO Daniel J. Moorhead purchased 4,340 common shares, 4,340 Series A Warrants and 4,340 Series B Warrants on 2026-07-29. All securities relate to Beyond Air common stock and are held directly after the transactions.

At what prices did the Beyond Air (XAIR) CFO acquire the stock and warrants?

The CFO bought common stock at $5.76 per share. Each Series A Warrant and Series B Warrant is exercisable for common stock at an exercise price of $5.51 per share, according to the filing details.

How many Beyond Air (XAIR) securities did the CFO buy in total?

Daniel J. Moorhead acquired 13,020 securities in total: 4,340 common shares, 4,340 Series A Warrants and 4,340 Series B Warrants. All transactions were reported as purchases and result in direct ownership of these positions.

When do the Beyond Air (XAIR) Series A and Series B Warrants held by the CFO expire?

The Series A Warrants expire on the earlier of one year from issuance or 45 days after FDA approval of the LungFit PH II premarket approval supplement. The Series B Warrants expire five years after their issuance date.

When are the Beyond Air (XAIR) warrants purchased by the CFO exercisable?

The filing states the Series A and Series B Warrants are exercisable immediately upon issuance, each allowing the holder to acquire common stock at an exercise price of $5.51 per share, subject to their respective expiration terms.

Does the Beyond Air (XAIR) Form 4 indicate any 10b5-1 trading plan for the CFO’s purchases?

The Form 4 indicates the Rule 10b5-1 checkbox is not marked, and no footnote describes these as plan-based trades. The reported transactions are simply characterized as purchases in open market or private transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/31/2026 - 06:21 PM Accepted by SEC EDGAR 07/31/2026 - 06:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MOORHEAD DANIEL J

(Last) (First) (Middle)

C/O BEYOND AIR, INC.

900 STEWART AVENUE, SUITE 301

(Street)

GARDEN CITY, NEW YORK 11530

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beyond Air, Inc. [ XAIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/29/2026		P		4,340	A	$5.76	4,340	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Warrant	$5.51	07/29/2026	07/29/2026	P		4,340		(1)	(2)	Common Stock	4,340	(3)	4,340	D
Series B Warrant	$5.51	07/29/2026	07/29/2026	P		4,340		(1)	(4)	Common Stock	4,340	(3)	4,340	D

Explanation of Responses:

1. Exercisable immediately upon issuance

2. Expiration on the earlier of (i) the first anniversary of their issuance or (ii) the date that is 45 days following approval by the FDA of the Company's pending premarket approval supplement for LungFit PH II

3. Each Series A Warrant and Series B Warrant was purchased together with one share of common stock for a combined purchase price of $5.76.

4. 5 years following date of issuance

	/s/ Daniel Moorhead	07/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)